1
|
Schwarting R, Behling E, Allen A, Arguello-Guerra V, Budak-Alpdogan T. CD30+ Lymphoproliferative Disorders as Potential Candidates for CD30-Targeted Therapies. Arch Pathol Lab Med 2022; 146:415-432. [PMID: 35299246 DOI: 10.5858/arpa.2021-0338-ra] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 09/14/2021] [Indexed: 11/06/2022]
Abstract
CONTEXT.— In the early 1980s, a monoclonal antibody termed Ki-1 was developed against a cell line derived from a patient with Hodgkin lymphoma. This antibody detected a limited number of benign activated lymphocytes in lymphoid tissue, whereas in Hodgkin lymphoma it appeared to be nearly specific for Reed-Sternberg cells and their mononuclear variants. Subsequent studies showed that Ki-1 expression defined a new type of lymphoma that was later designated anaplastic large cell lymphoma with or without anaplastic large cell kinase expression/translocation. In the past 30 years, numerous new lymphoma entities have been defined, many of which are variably positive for CD30. Many virally transformed lymphoproliferative disorders are also frequently positive for CD30. OBJECTIVE.— To illustrate the broad spectrum of CD30+ hematologic malignancies and to provide an update of CD30-targeted therapies. DATA SOURCES.— Personal experiences and published works in PubMed. CONCLUSIONS.— Because of its low expression in normal tissue, CD30 was studied as a therapeutic target for many years. However, the first functional humanized antibody against CD30 was developed only about 10 years ago. Brentuximab vedotin is a humanized anti-CD30 antibody linked to a cytotoxin, and was approved by the US Food and Drug Administration in 2012 for treating refractory Hodgkin lymphoma and anaplastic large cell lymphoma. Since then, the list of Food and Drug Administration-approved CD30-targeted hematologic malignancies has grown. Recently, the therapies using tumor antigen-specific chimeric antigen receptor T cells targeting CD30 have incited a great deal of enthusiasm and are studied in clinical trials.
Collapse
Affiliation(s)
- Roland Schwarting
- From the Department of Pathology, Cooper University Hospital and Cooper Medical School of Rowan University, Camden, New Jersey (Schwarting, Behling, Allen, Arguello-Guerra)
| | - Eric Behling
- From the Department of Pathology, Cooper University Hospital and Cooper Medical School of Rowan University, Camden, New Jersey (Schwarting, Behling, Allen, Arguello-Guerra)
| | - Ashleigh Allen
- From the Department of Pathology, Cooper University Hospital and Cooper Medical School of Rowan University, Camden, New Jersey (Schwarting, Behling, Allen, Arguello-Guerra)
| | - Vivian Arguello-Guerra
- From the Department of Pathology, Cooper University Hospital and Cooper Medical School of Rowan University, Camden, New Jersey (Schwarting, Behling, Allen, Arguello-Guerra)
| | - Tulin Budak-Alpdogan
- MD Anderson Cancer Center at Cooper, Department of Medicine, Cooper University Hospital, Cooper Medical School of Rowan University, Camden, New Jersey (Budak-Alpdogan)
| |
Collapse
|
2
|
Xu H, Liu Q, Li YM, Ma H, Hu HM. Acitretin combined with NB-UVB in the treatment of cutaneous CD30-positive anaplastic large cell lymphoma. Dermatol Ther 2019; 32:e12834. [PMID: 30659723 DOI: 10.1111/dth.12834] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/10/2018] [Revised: 01/06/2019] [Accepted: 01/15/2019] [Indexed: 11/29/2022]
Abstract
Cutaneous CD30+ lymphoproliferative disorders represent a spectrum of skin lymphatic reticular proliferative diseases, including lymphomatoid papulosis (LYP), primary cutaneous anaplastic large cell lymphoma (PC-ALCL), and borderline lesions between them. Although they all express CD30 as a phenotypic marker and share overlapping immunophenotypic features, they differ in clinical manifestations, pathological features, treatment, and prognosis. LYP is a kind of benign disease characterized by recurrent papules and nodules, and may spontaneously regress. PC-ALCL presents with solitary tumor or local grouped nodules characterized by large T-cells and may completely or partially resolve in fewer than half of cases. We reported a case of patient with clinical manifestation and pathologic features consistent with LYP in its early stages, which later turned into PC-ALCL. This patient was treated with acitretin combined with NB-UVB and had an obvious response.
Collapse
Affiliation(s)
- Hui Xu
- Department of Dermatology, The Affiliated Hospital of Jiangsu University, Zhenjiang, China.,Laboratory for Regeneration Medicine, Jiangsu University, Zhenjiang, China
| | - Qi Liu
- Department of Dermatology, The Affiliated Hospital of Jiangsu University, Zhenjiang, China.,Laboratory for Regeneration Medicine, Jiangsu University, Zhenjiang, China
| | - Yu-Mei Li
- Department of Dermatology, The Affiliated Hospital of Jiangsu University, Zhenjiang, China.,Laboratory for Regeneration Medicine, Jiangsu University, Zhenjiang, China
| | - Hong Ma
- Department of Dermatology, The Affiliated Hospital of Jiangsu University, Zhenjiang, China.,Laboratory for Regeneration Medicine, Jiangsu University, Zhenjiang, China
| | - Hui-Min Hu
- Department of Dermatology, The Affiliated Hospital of Jiangsu University, Zhenjiang, China.,Laboratory for Regeneration Medicine, Jiangsu University, Zhenjiang, China
| |
Collapse
|
3
|
Melchers R, Willemze R, Bekkenk M, de Haas E, Horvath B, van Rossum M, Sanders C, Veraart J, Vermeer M, Quint K. Evaluation of treatment results in multifocal primary cutaneous anaplastic large cell lymphoma: report of the Dutch Cutaneous Lymphoma Group. Br J Dermatol 2018; 179:724-731. [DOI: 10.1111/bjd.16501] [Citation(s) in RCA: 16] [Impact Index Per Article: 2.7] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 02/22/2018] [Indexed: 11/27/2022]
Affiliation(s)
- R.C. Melchers
- Department of Dermatology; Leiden University Medical Center; the Netherlands
| | - R. Willemze
- Department of Dermatology; Leiden University Medical Center; the Netherlands
| | - M.W. Bekkenk
- Department of Dermatology; Academic Medical Center and Vrije University Medical Center; Amsterdam the Netherlands
| | - E.R.M. de Haas
- Department of Dermatology; Erasmus Medical Center; Rotterdam the Netherlands
| | - B. Horvath
- Department of Dermatology; University Medical Center of Groningen; the Netherlands
| | - M.M. van Rossum
- Department of Dermatology; Radboud University Medical Center; Nijmegen the Netherlands
| | - C.J.G. Sanders
- Department of Dermatology; University Medical Center Utrecht; the Netherlands
| | - J.C.J.M. Veraart
- Department of Dermatology; Maastricht University Medical Center; the Netherlands
| | - M.H. Vermeer
- Department of Dermatology; Leiden University Medical Center; the Netherlands
| | - K.D. Quint
- Department of Dermatology; Leiden University Medical Center; the Netherlands
| |
Collapse
|
4
|
Stranzenbach R, Dippel E, Schlaak M, Stadler R. Brentuximab vedotin in CD30+cutaneous lymphoma: How do we treat, how shall we treat? A review of the literature. Br J Dermatol 2017; 177:1503-1509. [DOI: 10.1111/bjd.15801] [Citation(s) in RCA: 25] [Impact Index Per Article: 3.6] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 07/04/2017] [Indexed: 12/12/2022]
Affiliation(s)
- R. Stranzenbach
- Department of Dermatology, Venerology, Allergology and Phlebology; Johannes Wesling Medical Centre; University Hospital of Ruhr-University Bochum; Minden Germany
| | - E. Dippel
- Department of Dermatology; Klinikum Ludwigshafen; Skin Cancer Centre Rheinpfalz; Ludwigshafen Germany
| | - M. Schlaak
- Department of Dermatology and Venereology; University of Cologne; Cologne Germany
| | - R. Stadler
- Department of Dermatology, Venerology, Allergology and Phlebology; Johannes Wesling Medical Centre; University Hospital of Ruhr-University Bochum; Minden Germany
| |
Collapse
|
5
|
Enos TH, Feigenbaum LS, Wickless HW. Brentuximab vedotin in CD30+primary cutaneous T-cell lymphomas: a review and analysis of existing data. Int J Dermatol 2017; 56:1400-1405. [DOI: 10.1111/ijd.13696] [Citation(s) in RCA: 10] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 03/01/2017] [Revised: 05/25/2017] [Accepted: 06/09/2017] [Indexed: 11/27/2022]
Affiliation(s)
- Tyler H. Enos
- Department of Dermatology; University of Texas Southwestern; Dallas TX USA
| | | | | |
Collapse
|
6
|
Uzuncakmak TK, Akdeniz N, Karadag AS, Taskin S, Zemheri EI, Argenziano G. Primary cutaneous CD 30 (+) ALK (-) anaplastic large cell lymphoma with dermoscopic findings: a case report. Dermatol Pract Concept 2017; 7:59-61. [PMID: 28243498 PMCID: PMC5315044 DOI: 10.5826/dpc.0701a12] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [Key Words] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/11/2016] [Accepted: 10/24/2016] [Indexed: 11/12/2022] Open
Abstract
Primary cutaneous CD 30 (+) anaplastic large cell lymphoma (PCALCL) is a rare and indolent type of cutaneous T cell lymphoma, which usually presents as an asymptomatic solitary firm nodule that rapidly grows and often ulcerates without any systemic involvement. A 64-year-old female presented to our outpatient clinic with a one-year history of multiple pink nodular lesions on the chest, back and gluteal regions. Dermoscopic examination of the nodular lesions revealed pink-to-yellow structureless areas and arborizing-to-polymorphous vessels. Histopathologic examination was consistent with CD30 (+) anaplastic large cell lymphoma. Systemic involvement was not detected. Local radiotherapy for large nodules and surgical excision for small nodules were performed. The large nodules had totally regressed after 10 sessions of radiotherapy.
Collapse
Affiliation(s)
- Tugba K Uzuncakmak
- Department of Dermatology, Istanbul Medeniyet University, Istanbul, Turkey
| | - Necmettin Akdeniz
- Department of Dermatology, Istanbul Medeniyet University, Istanbul, Turkey
| | - Ayse S Karadag
- Department of Dermatology, Istanbul Medeniyet University, Istanbul, Turkey
| | - Secil Taskin
- Department of Dermatology, Istanbul Medeniyet University, Istanbul, Turkey
| | - Ebru I Zemheri
- Department of Pathology, Istanbul Medeniyet University, Pathology, Istanbul, Turkey
| | | |
Collapse
|
7
|
Berger GK, McBride A, Lawson S, Royball K, Yun S, Gee K, Bin Riaz I, Saleh AA, Puvvada S, Anwer F. Brentuximab vedotin for treatment of non-Hodgkin lymphomas: A systematic review. Crit Rev Oncol Hematol 2016; 109:42-50. [PMID: 28010897 DOI: 10.1016/j.critrevonc.2016.11.009] [Citation(s) in RCA: 50] [Impact Index Per Article: 6.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/01/2016] [Revised: 10/12/2016] [Accepted: 11/17/2016] [Indexed: 12/28/2022] Open
Abstract
BACKGROUND Brentuximab vedotin (BV) is an antibody-drug conjucate (ADC) comprising a CD30-directed antibody, conjugated to the microtubule-disrupting agent MMAE via a protease cleavable linker. BV is FDA approved for use in relapsed classical Hodgkin lymphoma (HL) and relapsed systemic anaplastic large cell lymphoma (sALCL). There are multiple publications for its utility in other malignancies such as diffuse large B-cell lymphoma (DLBCL), mycosis fungoides (MF), Sézary syndrome (SS), T-cell lymphomas (TCL), primary mediastinal lymphoma (PMBL), and post-transplant lymphoproliferative disorders (PTLD). We believe that BV could potentially provide a strong additional treatment option for patients suffering from NHL. OBJECTIVE Perform a systematic review on the use of BV in non-Hodgkin lymphoma (NHL) and other CD30+ malignancies in humans. DATA SOURCES We searched various databases including PubMed (1946-2015), EMBASE (1947-2015), and Cochrane Central Register of Controlled Trials (1898-2015). ELIGIBILITY CRITERIA Inclusion criteria specified all studies and case reports of NHLs in which BV therapy was administered. INCLUDED STUDIES A total of 28 articles met these criteria and are summarized in this manuscript. CONCLUSION Our findings indicate that BV induces a variety of responses, largely positive in nature and variable between NHL subtypes. With additional, properly powered prospective studies, BV may prove to be a strong candidate in the treatment of various CD30+ malignancies.
Collapse
Affiliation(s)
- Garrett K Berger
- College of Pharmacy, University of Arizona, Tucson, AZ, 85721, United States
| | - Ali McBride
- College of Pharmacy, University of Arizona, Tucson, AZ, 85721, United States
| | - Stephanie Lawson
- College of Pharmacy, University of Arizona, Tucson, AZ, 85721, United States
| | - Kelsey Royball
- College of Pharmacy, University of Arizona, Tucson, AZ, 85721, United States
| | - Seongseok Yun
- Departments of Medicine, University of Arizona, Tucson, AZ, 85721, United States
| | - Kevin Gee
- College of Medicine, University of Arizona, Tucson, AZ, 85721, United States
| | - Irbaz Bin Riaz
- Departments of Medicine, University of Arizona, Tucson, AZ, 85721, United States
| | - Ahlam A Saleh
- University of Arizona Health Sciences Library, University of Arizona, Tucson, AZ 85721, United States
| | - Soham Puvvada
- Departments of Medicine, University of Arizona, Tucson, AZ, 85721, United States
| | - Faiz Anwer
- Hematology, Oncology, Blood & Marrow Transplantation, Department of Medicine, University of Arizona, Tucson, AZ, 85721, United States.
| |
Collapse
|
8
|
Hapgood G, Pickles T, Sehn LH, Villa D, Klasa R, Scott DW, Gerrie AS, Gascoyne RD, Slack GW, Parsons C, Morris JW, Connors JM, Savage KJ. Outcome of primary cutaneous anaplastic large cell lymphoma: a 20-year British Columbia Cancer Agency experience. Br J Haematol 2016; 176:234-240. [DOI: 10.1111/bjh.14404] [Citation(s) in RCA: 16] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/29/2016] [Accepted: 08/22/2016] [Indexed: 11/30/2022]
Affiliation(s)
- Greg Hapgood
- Department of Medical Oncology; Centre for Lymphoid Cancer; British Columbia Cancer Agency; Vancouver BC Canada
| | - Tom Pickles
- Department of Radiation Oncology; British Columbia Cancer Agency; Vancouver BC Canada
| | - Laurie H. Sehn
- Department of Medical Oncology; Centre for Lymphoid Cancer; British Columbia Cancer Agency; Vancouver BC Canada
| | - Diego Villa
- Department of Medical Oncology; Centre for Lymphoid Cancer; British Columbia Cancer Agency; Vancouver BC Canada
| | - Richard Klasa
- Department of Medical Oncology; Centre for Lymphoid Cancer; British Columbia Cancer Agency; Vancouver BC Canada
| | - David W. Scott
- Department of Medical Oncology; Centre for Lymphoid Cancer; British Columbia Cancer Agency; Vancouver BC Canada
| | - Alina S. Gerrie
- Department of Medical Oncology; Centre for Lymphoid Cancer; British Columbia Cancer Agency; Vancouver BC Canada
| | - Randy D. Gascoyne
- Department of Pathology; Centre for Lymphoid Cancer; British Columbia Cancer Agency; Vancouver BC Canada
| | - Graham W. Slack
- Department of Pathology; Centre for Lymphoid Cancer; British Columbia Cancer Agency; Vancouver BC Canada
| | - Christina Parsons
- Department of Radiation Oncology; British Columbia Cancer Agency; Vancouver BC Canada
| | - James W. Morris
- Department of Radiation Oncology; British Columbia Cancer Agency; Vancouver BC Canada
| | - Joseph M. Connors
- Department of Medical Oncology; Centre for Lymphoid Cancer; British Columbia Cancer Agency; Vancouver BC Canada
| | - Kerry J. Savage
- Department of Medical Oncology; Centre for Lymphoid Cancer; British Columbia Cancer Agency; Vancouver BC Canada
| |
Collapse
|
9
|
Abstract
Primary cutaneous CD30⁺ lymphoproliferative disorders (LPDs) account for approximately 25% of cutaneous lymphomas. Although these LPDs are clinically heterogeneous, they can be indistinguishable histologically. Lymphomatoid papulosis rarely requires systemic treatment; however, multifocal primary cutaneous anaplastic large cell cutaneous lymphoma and large cell transformation of mycosis fungoides are typically treated systemically. As CD30⁺ LPDs are rare, there is little published evidence to support a specific treatment algorithm. Most studies are case reports, small case series, or retrospective reviews. This article discusses various treatment choices for each of the CD30⁺ disorders and offers practical pearls to aid in choosing an appropriate regimen.
Collapse
Affiliation(s)
- Lauren C Hughey
- University of Alabama at Birmingham, 1530 3rd Avenue South, EFH 414, Birmingham, AL 35294, USA.
| |
Collapse
|
10
|
McKelvie P, Yixing Lai F, Verma A, Bazargan A. Methotrexate-associated EBV-positive CD20-negative diffuse large B-cell lymphoma localized to skin presenting as multiple chronic lower leg ulcers. Leuk Lymphoma 2015; 57:456-460. [PMID: 26110881 DOI: 10.3109/10428194.2015.1049165] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022]
Affiliation(s)
- Penelope McKelvie
- a Department of Anatomical Pathology , St Vincent's Hospital Melbourne , Fitzroy , VIC , Australia
| | - Francis Yixing Lai
- b Department of Dermatology , St Vincent's Hospital Melbourne , Fitzroy , VIC , Australia
| | - Amit Verma
- b Department of Dermatology , St Vincent's Hospital Melbourne , Fitzroy , VIC , Australia
| | - Ali Bazargan
- c Department of Haematology , St Vincent's Hospital Melbourne , Fitzroy , VIC , Australia
| |
Collapse
|